FDG PET for Esophageal Cancer (Replaced with Section 220.6.17) - RETIRED | CMS Coverage Update

Summary: The Centers for Medicare & Medicaid Services modified its FDG PET coverage policy for esophageal cancer, effective May 15, 2026, retiring the standalone policy and folding it into Section 220.6.17 of the National Coverage Determinations manual. Here's what billing teams need to do.

This is a structural change to how CMS organizes FDG PET scan coverage, and it affects any practice or facility billing PET imaging for esophageal cancer under Medicare. The old standalone policy is gone. Section 220.6.17 now governs FDG PET billing for this indication. The policy does not list specific CPT or HCPCS codes in the available data, so your billing team should confirm applicable codes against the Section 220.6.17 document directly before the May 15, 2026 effective date.

---

Quick-Reference Table

Field	Detail Copy
Payer	CMS (Centers for Medicare & Medicaid Services)
Policy	FDG PET for Esophageal Cancer — Retired, Replaced by Section 220.6.17
Policy Code	N/A
Change Type	Modified (Retirement / Consolidation)
Effective Date	May 15, 2026
Impact Level	Medium
Specialties Affected	Oncology, Radiology, Nuclear Medicine, Gastroenterology, Thoracic Surgery
Key Action	Update all internal billing references from the retired standalone policy to NCD Section 220.6.17 before May 15, 2026

---

CMS FDG PET Esophageal Cancer Coverage Criteria and Medical Necessity Requirements 2026

The retired standalone policy covered FDG PET scans for esophageal cancer under a discrete National Coverage Determination. That policy no longer exists as a standalone document after May 15, 2026. Section 220.6.17 of the NCD Manual absorbs it.

This kind of consolidation is routine for CMS. It doesn't always signal a substantive change to coverage criteria — but it always creates billing risk if your team doesn't update its references. If your charge capture, prior authorization checklists, or internal billing guidelines still point to the retired policy, your documentation trail breaks. That creates exposure on audit.

The core medical necessity framework for FDG PET in esophageal cancer has historically required that imaging be used for one of several covered oncologic indications — initial staging, restaging after treatment, or evaluating response to therapy. CMS FDG PET coverage policy under Section 220.6.17 carries forward those distinctions, but your team should pull the current Section 220.6.17 text directly and confirm which indications remain covered, which are non-covered, and whether any medical necessity criteria shifted during the consolidation.

Medical necessity documentation for FDG PET scans in oncology is always under scrutiny. Medicare Administrative Contractors audit these claims closely. A retired policy reference in your documentation — even a minor one — gives a MAC auditor a reason to flag the claim.

---

CMS FDG PET Esophageal Cancer Coverage Criteria Under Section 220.6.17: What the Consolidation Means

Before this change, FDG PET for esophageal cancer had its own dedicated NCD. That structure made it easy to point a billing team at a single document. Section 220.6.17 is the broader NCD governing oncologic FDG PET across multiple cancer types. Esophageal cancer coverage now lives inside that larger framework.

This is similar to what CMS did with several oncologic imaging NCDs in the early 2020s — consolidating cancer-specific PET policies into the umbrella oncology PET NCD. The logic is administrative efficiency. The practical effect for billing teams is that the coverage rules are now embedded in a longer, more complex document. You need to know where to look.

The distinction between covered and non-covered indications matters here. Section 220.6.17 historically categorizes FDG PET claims into two buckets: "covered" indications where CMS has determined clinical evidence supports coverage, and "coverage with evidence development" (CED) indications where reimbursement is tied to participation in a qualifying registry or clinical trial. Whether esophageal cancer indications fall into covered or CED categories under the new consolidated structure is exactly what your billing team needs to verify before the effective date of May 15, 2026.

If any of your esophageal cancer PET claims fall under a CED indication, prior authorization requirements and registry enrollment documentation apply. Missing that documentation is a fast path to a claim denial.

---

CMS FDG PET Esophageal Cancer Exclusions and Non-Covered Indications

The available policy data for this retirement doesn't detail specific exclusions. That's the honest answer. The retirement notice points to Section 220.6.17 as the governing document, and that's where the exclusion language now lives.

What we do know from CMS's longstanding FDG PET coverage policy is that certain uses have historically been non-covered. Screening PET scans — imaging performed without a confirmed or suspected diagnosis — are not covered under Medicare. PET scans ordered without documented medical necessity, or without a treating physician's order tied to a specific clinical question, get denied.

For esophageal cancer specifically, the historical coverage framework excluded PET as a standalone screening tool and required imaging to be tied to active clinical management decisions. That framework is almost certainly preserved in Section 220.6.17, but confirm it. Don't assume the consolidation left everything unchanged.

If your team bills FDG PET for esophageal cancer in any edge-case scenario — post-treatment surveillance outside of standard restaging, for example — check Section 220.6.17's language explicitly. Edge cases that were tolerated under a more narrowly scoped standalone NCD may read differently under a broader consolidated policy.

---

Coverage Indications at a Glance

The available policy data does not include a granular, indication-level breakdown for this retirement notice. The table below reflects the historical CMS FDG PET coverage framework for esophageal cancer as carried into Section 220.6.17. Verify each indication against the current Section 220.6.17 text before billing after May 15, 2026.

---

CMS FDG PET Esophageal Cancer Billing Guidelines and Action Items 2026

This retirement has a hard deadline. The old standalone policy goes away on May 15, 2026. Here's what your billing team needs to do before that date.

Copy Action Items

---

CPT, HCPCS, and ICD-10 Codes for FDG PET Esophageal Cancer Under the Retired Policy and Section 220.6.17

Policy Code Data

The available policy data for this retirement does not list specific CPT, HCPCS, or ICD-10 codes. This post will not invent or guess codes.

Your team should pull the applicable codes directly from Section 220.6.17 of the CMS NCD Manual. FDG PET billing typically involves HCPCS codes for PET imaging, but the exact codes and their coverage status under Section 220.6.17 must be confirmed from the source document.

Where to Find the Correct Codes

Go to the CMS National Coverage Determinations Manual, Chapter 1, Section 220.6.17. The current version is available on CMS.gov. The section lists covered indications, CED indications, and the applicable HCPCS codes for each. Do not rely on a third-party summary — including this one — for billing decisions after May 15, 2026.

If your billing software or charge capture system uses code-to-NCD mappings, update those mappings to remove the retired standalone policy reference and point to Section 220.6.17. Most revenue cycle platforms that support NCD-based billing logic allow you to update policy references at the payer or code level.

---